Published in IRB on April 18, 2005
The quality of informed consent: mapping the landscape. A review of empirical data from developing and developed countries. J Med Ethics (2012) 1.69
Participants' understanding of informed consent in clinical trials over three decades: systematic review and meta-analysis. Bull World Health Organ (2015) 1.34
Voluntary participation and informed consent to international genetic research. Am J Public Health (2006) 1.32
Consent and community engagement in diverse research contexts. J Empir Res Hum Res Ethics (2013) 1.26
Why do individuals agree to enrol in clinical trials? A qualitative study of health research participation in Blantyre, Malawi. Malawi Med J (2008) 1.06
Tailoring information provision and consent processes to research contexts: the value of rapid assessments. J Empir Res Hum Res Ethics (2012) 1.01
Using formative research to develop a context-specific approach to informed consent for clinical trials. J Empir Res Hum Res Ethics (2006) 0.94
Improving understanding of clinical trial procedures among low literacy populations: an intervention within a microbicide trial in Malawi. BMC Med Ethics (2012) 0.93
Voluntary participation and comprehension of informed consent in a genetic epidemiological study of breast cancer in Nigeria. BMC Med Ethics (2014) 0.91
Improving participant understanding of informed consent in an HIV-prevention clinical trial: a comparison of methods. AIDS Behav (2012) 0.88
Reported consent processes and demographics: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med (2015) 0.82
Empirical evaluation of the need for 'on-going consent' in clinical research. AIDS (2011) 0.81
Comparing the understanding of subjects receiving a candidate malaria vaccine in the United States and Mali. Am J Trop Med Hyg (2010) 0.80
Comparison of closed-ended, open-ended, and perceived informed consent comprehension measures for a mock HIV prevention trial among women in Tanzania. PLoS One (2014) 0.79
Ethical issues in research involving minority populations: the process and outcomes of protocol review by the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University, Thailand. BMC Med Ethics (2013) 0.77
The limitations of "vulnerability" as a protection for human research participants. Am J Bioeth (2004) 14.06
What makes clinical research in developing countries ethical? The benchmarks of ethical research. J Infect Dis (2004) 9.65
The Affordable Care Act and the future of clinical medicine: the opportunities and challenges. Ann Intern Med (2010) 9.59
Broad Consent for Research With Biological Samples: Workshop Conclusions. Am J Bioeth (2015) 8.99
Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med (2005) 8.25
Dealing with the long-term social implications of research. Am J Bioeth (2011) 5.41
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst (2009) 5.40
Results of the National Initiative for Cancer Care Quality: how can we improve the quality of cancer care in the United States? J Clin Oncol (2006) 5.40
How do institutional review boards apply the federal risk and benefit standards for pediatric research? JAMA (2004) 4.65
Principles for allocation of scarce medical interventions. Lancet (2009) 4.55
Ethical issues concerning research in complementary and alternative medicine. JAMA (2004) 4.48
HIV/AIDS in Asia. Lancet (2004) 4.45
The obligation to participate in biomedical research. JAMA (2009) 4.34
An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med (2010) 4.24
The accuracy of surrogate decision makers: a systematic review. Arch Intern Med (2006) 4.17
Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB (2003) 3.82
Enduring and emerging challenges of informed consent. N Engl J Med (2015) 3.79
Clinical trials and medical care: defining the therapeutic misconception. PLoS Med (2007) 3.77
Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One (2012) 3.69
Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med (2002) 3.62
Oversight of human participants research: identifying problems to evaluate reform proposals. Ann Intern Med (2004) 3.58
Shared decision making to improve care and reduce costs. N Engl J Med (2013) 3.48
SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infect Control Hosp Epidemiol (2010) 3.44
The cost of marginal medicine is too high. MedGenMed (2005) 3.33
The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr (2005) 3.18
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit. JAMA (2005) 3.14
The cost of institutional review boards in academic medical centers. N Engl J Med (2005) 3.06
Reducing legal risk by practicing patient-centered medicine. Arch Intern Med (2002) 2.98
Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database. Clin Infect Dis (2009) 2.89
Prescribing "placebo treatments": results of national survey of US internists and rheumatologists. BMJ (2008) 2.84
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79
Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol (2006) 2.72
Evidence of a previously undocumented epidemic of HIV infection among men who have sex with men in Bangkok, Thailand. AIDS (2005) 2.58
Informed Consent. N Engl J Med (2017) 2.56
Developing a system to assess the quality of cancer care: ASCO's national initiative on cancer care quality. J Clin Oncol (2004) 2.52
Medicare's requirement for research participation as a condition of coverage: is it ethical? JAMA (2006) 2.43
Research with stored biological samples: what do research participants want? Arch Intern Med (2005) 2.43
Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis (2010) 2.41
The prognosis for changes in end-of-life care after the Schiavo case. Health Aff (Millwood) (2005) 2.40
Patients' views on financial conflicts of interest in cancer research trials. N Engl J Med (2006) 2.29
Ethics of phase 1 oncology studies: reexamining the arguments and data. JAMA (2003) 2.28
A family's request for complementary medicine after patient brain death. JAMA (2008) 2.27
Protecting communities in health research from exploitation. Bioethics (2006) 2.26
Moral distress: a growing problem in the health professions? Hastings Cent Rep (2010) 2.23
Trends in HIV Prevalence, Estimated HIV Incidence, and Risk Behavior Among Men Who Have Sex With Men in Bangkok, Thailand, 2003–2007. J Acquir Immune Defic Syndr (2010) 2.23
Examining the ethics of clinical use of unproven interventions outside of clinical trials during the Ebola epidemic. Am J Bioeth (2015) 2.20
Ethical guidance on the use of life-sustaining therapies for patients with Ebola in developed countries. Ann Intern Med (2014) 2.19
Use of a patient preference predictor to help make medical decisions for incapacitated patients. J Med Philos (2014) 2.18
US health aid beyond PEPFAR: the Mother & Child Campaign. JAMA (2008) 2.17
The 50th anniversary of the Declaration of Helsinki: progress but many remaining challenges. JAMA (2013) 2.16
HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study. Clin Infect Dis (2011) 2.08
Treatment decision making for incapacitated patients: is development and use of a patient preference predictor feasible? J Med Philos (2014) 2.05
Deception in research on the placebo effect. PLoS Med (2005) 2.05
A systematic review of the empirical literature evaluating IRBs: what we know and what we still need to learn. J Empir Res Hum Res Ethics (2011) 2.03
Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis (2012) 2.01
Community permission for medical research in developing countries. Clin Infect Dis (2005) 2.01
More than the money: a review of the literature examining healthy volunteer motivations. Contemp Clin Trials (2010) 1.92
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet (2006) 1.91
Paying research subjects: an analysis of current policies. Ann Intern Med (2002) 1.90
The standard of care debate: can research in developing countries be both ethical and responsive to those countries' health needs? Am J Public Health (2004) 1.88
The patents-based pharmaceutical development process: rationale, problems, and potential reforms. JAMA (2005) 1.83
Research on stored biological samples: views of African American and White American cancer patients. Am J Med Genet A (2006) 1.80
What are biomarkers? Curr Opin HIV AIDS (2010) 1.80
The ethics of paying for children's participation in research. J Pediatr (2002) 1.80
What is a "minor" increase over minimal risk? J Pediatr (2005) 1.79
Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol (2010) 1.76
Participants in phase 1 oncology research trials: are they vulnerable? Arch Intern Med (2008) 1.74
Informed consent for research and authorization under the Health Insurance Portability and Accountability Act Privacy Rule: an integrated approach. Ann Intern Med (2006) 1.73
The invisible hand in clinical research: the study coordinator's critical role in human subjects protection. J Law Med Ethics (2002) 1.72
Ethical climate, ethics stress, and the job satisfaction of nurses and social workers in the United States. Soc Sci Med (2007) 1.72
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol (2008) 1.71
Will physicians lead on controlling health care costs? JAMA (2013) 1.71
Ancillary care obligations of medical researchers. JAMA (2009) 1.70
The quality of informed consent: mapping the landscape. A review of empirical data from developing and developed countries. J Med Ethics (2012) 1.69
One-year experience of nucleic acid technology testing for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus in Thai blood donations. Transfusion (2009) 1.68
Health care reform and cost control. N Engl J Med (2010) 1.66
Ethics. The ethics of international research with abandoned children. Science (2007) 1.65
Is emergency research without initial consent justified?: the consent substitute model. Arch Intern Med (2010) 1.65
Frequency, type, and monetary value of financial conflicts of interest in cancer clinical research. J Clin Oncol (2007) 1.65
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS (2004) 1.62
A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis (2005) 1.62
Why patients continue to participate in clinical research. Arch Intern Med (2008) 1.62
Research on stored biological samples: the views of Ugandans. IRB (2005) 1.59
Clinician integrity and limits to patient autonomy. JAMA (2011) 1.55
Ethical considerations in HIV cure research: points to consider. Curr Opin HIV AIDS (2013) 1.55
Ending concerns about undue inducement. J Law Med Ethics (2004) 1.55
WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf (2013) 1.53
Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood (2007) 1.52